Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation

Article Abstract:

A survey of 350 patients receiving chemotherapy for acute myelogenous leukemia from 1979 to 1990 found that only 58% of those eligible to receive a bone marrow transplant actually got one. Eligible patients were those younger than 40 who were in remission and who had an HLA-identical sibling donor. Only 45% of patients under 40 who had an HLA match received a bone marrow transplant. Refractory disease, a short remission and refusal to undergo the treatment were some of the reasons eligible patients did not receive a transplant. Ten percent of eligible patients declined the procedure.

Care and treatment, Planning, Bone marrow, Bone marrow transplantation, Transplantation of organs, tissues, etc., Organ transplantation, Tissue transplantation, Transplantation, Acute leukemia

---

Altered bone and mineral metabolism in patients receiving imatinib mesylat

Article Abstract:

A study was conducted to observe hypophosphatemia and a series of associated changes in bone and mineral metabolism that occurred in some patients receiving imatinib for either (chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors. Chronic, untreated hypophosphatemia could result in impaired bone mineralization, rickets, and osteomalacia, so routine monitoring of serum phosphate and vitamin D during imatinib therapy might be advisable for prompt phosphate replacement.

Science & research, England, Research, Causes of, Hypophosphatemia, Mineral metabolism

---

Another look at imatinib mesylate

Article Abstract:

Number of studies conducted among patients treated with imatinib for chronic myelogenous leukemia (CML) indicates that there is an association between imatinib mesylate and congestive heart failure. The findings have suggested that imatinib causes stress in the endoplasmic reticulum, which in turn induces cardiomyocyte cell death, suggesting that the endoplasmic reticulum stress response is pivotal to the cardiotoxicity associated with imatinib.

Risk factors, Drug therapy, Endoplasmic reticulum, Chronic myeloid leukemia, Clinical report

Similar abstracts:

• Abstracts: Disappointments in treating acute leukemia in the elderly. Inheritance of a cancer-associated MLH1 germ-line epimutation
• Abstracts: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. New oral anticoagulants show promise
• Abstracts: Hepatitis E virus and chronic hepatitis in organ-transplant recipients
• Abstracts: Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae
• Abstracts: Hematopoietic stem-cell transplantation. MicroRNAs as therapeutic targets. Chimerism and tolerance in a recipient of a deceased-donor liver transplant

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.